Parkinson disease
Conditions
Interventions
Control group (n = 31) with Parkinson's disease who receive 24 therapys with muslce strengh, divided into 3 blocks of 8 therapies that follow gradual evolution of the exercises, often 3 times per week
Other
E02.779
G11.427.690
E01.370.600.250
Sponsors
Universidade Estadual de Londrina
Universidade Estadual de Londrina
Eligibility
Age
50 Years to 85 Years
Inclusion criteria
Inclusion criteria: Medical diagnosis of Parkinson's disease, according to the criteria of the London Brain Bank (Uk Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria): First step: Bradykinesia associated with at least one of the following symptoms: resting tremor, muscle stiffness or alteration of postular reflexes; Second stage: diagnostic exclusion criteria; Lack of clinical signs of secondary forms of parkinsonism or parkinsonism; No change in eye movements, dementia in the first year of symptoms, cerebellar ataxia, severe dysautonomia, falls and serious imbalance in the first year of symptoms, etc. Third stage: Criteria for diagnoses support; Home unilateral and asymmetrical course; The first side is affected the most committed throughout evolution; Presence of resting tremor; Progression of symptoms; Excellent response to levodopa; Response to levodopa lasting five or more years; Levodopa-induced dyskinesia; Clinical course of ten years or more. Individuals over 50 years. Do not institutionalized. Mini Mental score at least that does not characterize cognitive impairment. Hohen Yahr 1.5 to 3.0. What part of the project accept and sign the consent according term to the criteria of the Ethics Committee of the Universidade Estadual de Londrina, according to the parecer 466/2912 (CNS).
Exclusion criteria
Exclusion criteria: Individuals who perform other therapeutic treatment beyond drug that has change in medication during the study or those with associated diseases, such as neurological disorders, severe heart disease, amputations, cognitive deficits or understanding. Change in the stabilization of the antiparkinsonian doses throughout the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improve balance verified by the force BIOMEC 400 platform (EMG System of Brazil) between pre- and post-intervention variables: amplitude (Hz), velocity (centimeters/second) and the center of pressure of the feet area (cm2). Significance level of 5% is adopted for the analysis. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Improve gait verified by video analysis for variable speed (meters/second), total distance time (seconds) and gait cadence (steps/second) and foot print test for the variables step and stride length (cm) between the pre and post intervention analysis. Significance level of 5% is adopted for the analysis. ;2) Improve quality of life assessed by questionnaires Questionnaire for Parkinson's disease (PDQ-39) and the minimum score (zero points) indicates a better perception of patients about their quality of life and Quality of Life Questionnaire for Parkinson Disease (PDQL) and the maximum score (185 points) indicates a better perception of patients about their quality of life; Significance level of 5% is adopted for the analysis.;3) Improvement in functional independence (clinical signs and symptoms) verified by the Unified Rating Scale for Parkinson's Disease: - item II - daily activities (score 0-52 points) and the item III - motor (score of 0 - 108 points), totaling 27 items. The lower the score on the scale indicates greater independence. Significance level of 5% is adopted for the analysis.;4) Improvement of depression assessed by the Geriatric Depression Scale: It is a test for detection depressive symptoms in the elderly, with 15 questions. The result of 5 or more points diagnosing depression. Expected to obtain lower scores than 5 post-intervention assessment. Significance level of 5% is adopted for the analysis. | — |
Countries
Brazil
Contacts
Public ContactSuhaila Smaili Santos
Universidade Estadual de Londrina
Outcome results
None listed